Who Owns Medica Group Company?

Who currently owns Medica Group?

In May 2023 Medica Group plc was acquired by funds advised by private equity firm IK Partners, taking the teleradiology leader private after a seven-year LSE listing. The deal shifted control from public shareholders to institutional ownership focused on growth.

Ownership now rests with IK Partners’ advised funds, which are steering international expansion, subspecialty reporting and clinical trial imaging services; see Medica Group Porter's Five Forces Analysis.

Founders and early ownership of Medica Group trace to 2004 when clinician-entrepreneurs structured the business to deliver urgent and routine teleradiology to NHS trusts, with founders holding a clear majority stake that shaped early governance.

Founding team

Medica was co-founded in 2004 by Dr. Stephen Davies, Dr. Anthony Tony Newman-Sanders and operational partner Richard Jones to provide teleradiology services to NHS trusts.

Initial equity split

At inception founders held a combined majority exceeding 70%, with remaining equity among clinician-reporters and a small friends-and-family group funding IT and compliance.

Founder agreements

Agreements included 4‑year vesting tied to service milestones, non-compete and non-solicit clauses, and buy-sell provisions giving the company first refusal on departing clinicians’ shares.

Early capital rounds

Between 2009–2013 angel backers and clinician-shareholders provided growth capital to scale PACS connectivity and out-of-hours capacity, increasing operational reach.

Minority investor entry

By 2013–2014 healthcare-focused investors took minority stakes, diluting founder holdings in exchange for expansion capital and governance professionalisation.

Founder transitions

Prior to later exits or IPO planning, some founders partially exited or reduced stakes while retaining board advisory roles to align control with scalability and quality standards.

Early ownership changes set the stage for the Medica Group ownership history: founder-majority control gave way to institutional minority stakes, preserving clinical governance while enabling growth.

Key early ownership facts

Founders, governance terms and funding milestones that shaped Medica Group shareholders and corporate structure.

• Founders: Dr. Stephen Davies; Dr. Anthony Tony Newman-Sanders; Richard Jones
• Founders held > 70% at inception
• 4‑year vesting, non-compete/non-solicit, buy-sell first refusal
• 2009–2014: angel and minority investor rounds scaled PACS and out-of-hours capacity

Further reading on strategic positioning and investor relations is available in the article Marketing Strategy of Medica Group

Medica Group SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events reshaping Medica Group ownership include the March 2017 IPO on the London Stock Exchange, a period of strategic acquisitions and growth through 2020–2022, and the May 2023 take‑private by IK Partners that concentrated control in private equity funds while enabling minority rollover by senior management.

Post‑transaction the Medica Group ownership shifted from diversified public institutional holders (BlackRock, Fidelity, Standard Life Aberdeen/abrdn, Liontrust, Canaccord and others) and founders with single‑digit stakes to majority control by IK Partners’ investment vehicles (IK IX funds) with selected senior management holding minority rollover equity; there is no government stake and no founder retains controlling ownership.

Ownership implications and strategic focus

Private equity ownership under IK Partners has accelerated tech investment, M&A optionality and tighter governance metrics.

• Majority owner: IK Partners’ funds (IK IX) post‑mid‑2023
• Minority rollover: selected senior management retained equity
• Pre‑deal public holders exited for cash at 212p per share
• Strategic focus: AI triage, workflow orchestration, international expansion (including RadMD)

For additional context on revenue mix and business lines tied to ownership‑driven strategy, see Revenue Streams & Business Model of Medica Group.

Medica Group PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Post-privatization, Medica Group’s board is composed of IK Partners appointees, Medica executive directors and independent non-executives, providing governance oversight aligned with the private equity parent and management.

The voting framework within the IK-controlled private holding companies follows a one-share-one-vote model; IK-controlled entities hold majority voting power while management holds rollover minority equity through incentive structures such as growth shares and sweet equity tied to performance hurdles.

Board composition and voting summary

IK Partners holds majority control; management retains aligned minority stakes via performance-linked equity.

• Board includes IK Healthcare team appointees and Medica’s CEO and CFO
• Independent non-executives provide sector and NHS operational expertise
• Standard one-share-one-vote structure; no dual-class or golden shares disclosed
• Pre-2023 PLC governance featured an independent chair and no notable activist campaigns

For further background on ownership and strategic direction see Growth Strategy of Medica Group.

Medica Group Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Since the 2023 take‑private at 212p, Medica Group ownership has centralized with IK Partners as majority owner and management retaining a minority stake; founder holdings had already diluted pre‑sale and no public market transactions have occurred post‑delisting.

Industry context: NHS England reported persistent consultant radiologist shortages and imaging backlogs through 2024, supporting outsourced demand; private equity deal activity in teleradiology and imaging services increased across Europe and the US, with AI tie‑ups and cross‑border roll‑ups becoming common.

Ownership concentration

IK Partners holds the majority stake post‑take‑private; management retains a minority roll for alignment and incentive purposes.

Financing and capital structure

Capital structure changes since 2023 have been private, focused on acquisition financing and management incentive plans rather than public buybacks or secondaries.

Growth strategy

Priorities include scaling RadMD in the US, pursuing continental European bolt‑ons, and investing in AI and quality assurance to reduce NHS cyclicality exposure.

Exit optionality

Typical PE hold period of 3–5 years implies medium‑term options: trade sale to a strategic imaging platform or potential re‑IPO; no timeline publicly committed by management or IK.

For additional context on market positioning and client segments, see Target Market of Medica Group.

Medica Group Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔